GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Tax Expense

ValiRx (LSE:VAL) Tax Expense : £-0.14 Mil (TTM As of Jun. 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Tax Expense?

ValiRx's tax expense for the months ended in Jun. 2024 was £-0.05 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.14 Mil.


ValiRx Tax Expense Historical Data

The historical data trend for ValiRx's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Tax Expense Chart

ValiRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.29 -0.08 -0.13 -0.19 -0.18

ValiRx Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.12 -0.09 -0.09 -0.05

ValiRx Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ValiRx  (LSE:VAL) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


ValiRx Tax Expense Related Terms

Thank you for viewing the detailed overview of ValiRx's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx Business Description

Traded in Other Exchanges
Address
D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.

ValiRx Headlines

From GuruFocus

Valaris Ltd (VAL) Shares Down 4.61% on Dec 6

By GuruFocus News 12-06-2024

Valaris Ltd (VAL) Stock Price Up 3.04% on Nov 4

By GuruFocus News 11-04-2024

Q2 2024 Valaris Ltd Earnings Call Transcript

By GuruFocus News 10-09-2024

Valaris Ltd (VAL) Trading Down 3.18% on Nov 8

By GuruFocus News 11-08-2024

Valaris Ltd (VAL) Stock Price Up 3.12% on Feb 4

By GuruFocus News 02-04-2025

Valaris Ltd (VAL) Stock Price Down 4.37% on Nov 1

By GuruFocus News 11-01-2024

Valaris Reports Third Quarter 2024 Results

By Business Wire 10-30-2024

FMR LLC Reduces Stake in Valaris Ltd by 30.56%

By GuruFocus News 02-12-2025